Telix Pharmaceuticals’ (TLX) “Outperform” Rating Reaffirmed at Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a research report issued on Wednesday, Benzinga reports. They currently have a $22.00 target price on the stock. Wedbush’s price target points to a potential upside of 84.10% from the company’s current price.

A number of other equities analysts also recently weighed in on TLX. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $20.50.

Telix Pharmaceuticals Stock Up 5.7%

Telix Pharmaceuticals stock opened at $11.95 on Wednesday. The stock has a 50-day simple moving average of $11.32 and a 200 day simple moving average of $10.41. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $13.11.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XY Capital Ltd grew its holdings in Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after purchasing an additional 58,739 shares during the period. Hennion & Walsh Asset Management Inc. bought a new position in shares of Telix Pharmaceuticals during the second quarter worth $1,731,000. Bank of America Corp DE grew its holdings in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after buying an additional 8,423 shares during the period. Lazard Asset Management LLC increased its position in shares of Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after buying an additional 39,400 shares in the last quarter. Finally, Private Advisor Group LLC raised its stake in Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after buying an additional 128,070 shares during the period.

Key Stories Impacting Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Strategic radiopharmaceutical expansion: Telix agreed to acquire ITM in a deal valued at up to $2.35 billion, including $1.65 billion in upfront consideration and up to $700 million in additional payments tied to regulatory and sales milestones. The combination is intended to create a larger radiopharmaceutical platform and strengthen Telix’s access to medical radioisotopes. Telix Pharmaceuticals Lands $2.35 Billion Deal
• Positive Sentiment: Improved analyst sentiment: Royal Bank of Canada upgraded Telix from “Hold” to “Moderate Buy,” potentially supporting the stock by signaling greater confidence in the company’s outlook following the ITM announcement. RBC Upgrades Telix Pharmaceuticals
• Positive Sentiment: Pipeline and supply rationale: Management’s research and development presentation emphasized Telix’s oncology pipeline and the strategic importance of securing isotope supply, which could improve manufacturing reliability and support future product launches. Telix Research and Development Day Transcript
• Neutral Sentiment: Share-issuance flexibility: Telix received ASX waivers concerning the timing of shares issued as acquisition consideration, facilitating the transaction but highlighting that equity issuance will be an important part of funding the deal. Telix Receives ASX Waivers
• Negative Sentiment: Deal-related selling pressure: Telix’s stock fell sharply after the announcement as investors focused on the transaction’s size, potential dilution from issuing Telix shares, integration risk and the need for ITM’s lead drug to achieve approval and sales targets. Telix Stock Drops Following ITM Merger Deal

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.